Case Report: Stepwise Anti-Inflammatory and Anti-SARS-CoV-2 Effects Following Convalescent Plasma Therapy With Full Clinical Recovery

In these times of COVID-19 pandemic, concern has been raised about the potential effects SARS-CoV-2 infection on immunocompromised patients, particularly those receiving B-cell depleting agents and having therefore a severely depressed humoral response. Convalescent plasma can be therapeutic option for patients. Understanding underlying mechanisms convalescent is crucial to optimize such approach. Here, we describe patient who was deeply immunosuppressed following rituximab (anti-CD20 monoclonal antibody) concomitant chemotherapy chronic lymphoid leukemia. His long-term severe T B cell lymphopenia allowed evaluate treatment plasma. Therapeutic outcome monitored at clinical, biological radiological level. Moreover, anti-SARS-CoV-2 antibody titers (IgM, IgG IgA) neutralizing activity were assessed over time before after transfusions, alongside RNA quantification virus isolation from upper respiratory tract. Already first cycle transfusion, experienced rapid improvement pneumonia, inflammation blood counts, which may related immunomodulatory properties Subsequently, cumulative increase in antibodies due three additional transfusions associated with progressive finally complete viral clearance, resulting full clinical recovery. this case-report, administration revealed stepwise effect an initial anti-inflammatory followed by clearance. These data have implications more extended use future